key: cord-0865938-65jy69vs
authors: Case, James Brett; Mackin, Samantha; Errico, John; Chong, Zhenlu; Madden, Emily A.; Guarino, Barbara; Schmid, Michael A.; Rosenthal, Kim; Ren, Kuishu; Jung, Ana; Droit, Lindsay; Handley, Scott A.; Halfmann, Peter J.; Kawaoka, Yoshihiro; Crowe, James E.; Fremont, Daved H.; Virgin, Herbert W.; Loo, Yueh-Ming; Esser, Mark T.; Purcell, Lisa A.; Corti, Davide; Diamond, Michael S.
title: Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains
date: 2022-03-18
journal: bioRxiv
DOI: 10.1101/2022.03.17.484787
sha: fb5ff634eb670d2eb31d25044c7251a931663f7a
doc_id: 865938
cord_uid: 65jy69vs

Omicron variant strains encode large numbers of changes in the spike protein compared to historical SARS-CoV-2 isolates. Although in vitro studies have suggested that several monoclonal antibody therapies lose neutralizing activity against Omicron variants1-4, the effects in vivo remain largely unknown. Here, we report on the protective efficacy against three SARS-CoV-2 Omicron lineage strains (BA.1, BA.1.1, and BA.2) of two monoclonal antibody therapeutics (S309 [Vir Biotechnology] monotherapy and AZD7442 [AstraZeneca] combination), which correspond to ones used to treat or prevent SARS-CoV-2 infections in humans. Despite losses in neutralization potency in cell culture, S309 or AZD7442 treatments reduced BA.1, BA.1.1, and BA.2 lung infection in susceptible mice that express human ACE2 (K18-hACE2). Correlation analyses between in vitro neutralizing activity and reductions in viral burden in K18-hACE2 or human Fcγ R transgenic mice suggest that S309 and AZD7442 have different mechanisms of protection against Omicron variants, with S309 utilizing Fc effector function interactions and AZD7442 acting principally by direct neutralization. Our data in mice demonstrate the resilience of S309 and AZD7442 mAbs against emerging SARS-CoV-2 variant strains and provide insight into the relationship between loss of antibody neutralization potency and retained protection in vivo.

We next evaluated whether the differences in neutralizing activity of S309-LS and 147 AZD7442-YTE/TM correlated with lung viral burden after infection with the three Omicron 148 strains. The change in AZD7442-YTE/TM neutralizing activity associated directly with the 149 differences in lung viral burden of each Omicron variant (Fig. 2k) . This relationship is consistent 150 with its likely mechanism of action, virus neutralization and inhibition of entry 17, 18 . The 151 AZD7442-TM version we used, like the clinical drug Evusheld, encodes for modifications in the 152 constant region of the mAb heavy chains that profoundly decrease binding to Fc-gamma 153 receptors (FcγRs) and complement components ( 19 and Fig 3a) . In comparison, for S309-LS, a 154 similar direct correlation between changes in neutralization potency in vitro and reductions in 155 viral burden in vivo was not observed (Fig. 2l) , indicating a possible additional protective 156 mechanism beyond virus neutralization. 157 158

To evaluate a potential role for Fc effector functions in S309 mAb-mediated protection 160 against Omicron strains, we engineered loss-of-function GRLR mutations (G236R, L328R) into 161 the Fc domain of the human IgG1 heavy chain of S309; these substitutions eliminate antibody 162 binding to FcγRs 13 . Introduction of the GRLR mutations abrogated binding to hFcγRI and 163 hFcγRIIIa, as expected ( Fig. 3a) but did not affect neutralization of the SARS-CoV-2 strains 164 (Extended Data Fig. 4) . Next, we compared VIR-7831 (the clinical form of S309-LS) and 165 S309-GRLR in an in vitro antibody-dependent cell cytotoxicity (ADCC) assay. When target cells 166 expressing similar levels of Wuhan-D614, BA.1, or BA.2 spike proteins on the cell surface (Fig.  167 3b) were incubated with VIR-7831 mAb, we observed some reductions in binding to Omicron 168 spike proteins compared to mAb S2X324, an antibody that retains neutralizing activity against 169 BA.1, BA.1.1, and BA.2 and engages a distinct epitope in the RBM 4 . Despite the differences in 170 binding, target cells expressing Wuhan-D614, BA.1, or BA.2 spike proteins were lysed 171 efficiently by primary natural killer (NK) cells (antibody-dependent cellular cytotoxicity, 172 ADCC) isolated from four donors by VIR-7831 but not by S309-GRLR (Fig. 3c, d, Extended  173 Data Fig. 5) . Similarly, primary CD14 + monocytes isolated from five donors mediated 174 comparable antibody-dependent cellular phagocytosis (ADCP) of target cells expressing Wuhan-175 D614, BA.1, or BA.2 spike proteins by VIR-7831 but not by S309-GRLR (Fig. 3e, f, Extended  176 Data Fig. 6, 7) . 177

To evaluate the role of effector functions in vivo in S309-LS mAb-mediated protection 178 against Omicron variant strains, we treated K18-hACE2 mice with a single 200 μ g (~10 mg/kg 179 total) dose of S309-GRLR mAb by intraperitoneal injection one day prior to intranasal 180 inoculation with D614G, BA.1, or BA.2 strains. At 6 (BA.2) or 7 (D614G and BA.1) dpi, viral 181 RNA levels in the lungs, nasal turbinates, and nasal washes were measured ( Fig. 3g-i) . Although 182 S309-GRLR treatment reduced viral burden in the lung and nasal turbinates of D614G-infected 183 mice, it did not limit infection by BA.1 and BA.2 strains in the tissues tested. To corroborate 184 these findings, we treated human FcγR (hFcγR) transgenic C57BL/6 mice 20 with a single 3 185 mg/kg dose of S309-LS or S309-GRLR mAbs one day prior to inoculation with a SARS-CoV-2 186 Beta (B.1.351) isolate; we used the Beta isolate for these studies because Omicron strains 187 replicate poorly in conventional C57BL/6 mice lacking expression of hACE2 16 . At 2 or 4 dpi, 188 S309-LS mAb-treated hFcγR mice showed markedly reduced levels of viral RNA (49 to 127-189 fold) or infectious virus (56-to 538-fold) in the lung compared to the isotype control-treated 190 mice, whereas animals administered S309-GRLR showed smaller (2.3-to 13-fold) differences, 191 most of which did not attain statistical significance (Fig. 3j, k) We compared the in vitro neutralizing activity and in vivo efficacy of S309 (parent mAb 208 of Sotrovimab) and AZD7442 (Evusheld) that correspond to the clinically-used products. Our 209 study establishes the utility of S309 and AZD7442 mAbs against highly divergent SARS-CoV-2 210 variants. Despite losses in neutralization potency against BA.1, BA.1.1, and BA.2 strains, S309-211 LS and AZD7442-TM reduced viral burden and pro-inflammatory cytokine levels in the lungs of 212 K18-hACE2 mice, albeit with some differences in activity and mechanisms of action. Although 213 AZD7442-TM had a limited protective effect on viral burden in the nasal washes and nasal 214 turbinates of infected mice, this was not entirely unexpected, as studies with the parental mAbs 215 COV2-2196 and COV2-2130 showed less protection in nasal washes than lungs against multiple 216 SARS-CoV-2 VOC 23 . Moreover, studies in non-human primates with anti-SARS-CoV-2 human 217 mAbs showed the concentrations in nasopharyngeal washes are approximately 0.1% of those 218 found in the serum 24 , which likely explains their diminished benefit in this tissue compartment. 219

We also assessed whether the reductions in mAb neutralization potency against Omicron (https://opendata.ncats.nih.gov/covid19/animal). Furthermore, they also demonstrate that for 238 some mAbs, Fc effector functions can compensate for losses in neutralization potency against 239 SARS-CoV-2 variants and act as a protective mechanism in vivo. Thus, effector functions can 240 contribute to resilience of some mAbs against Omicron and other VOC 30,31 . We speculate that 241 the stoichiometric threshold and antibody occupancy requirements for Fc effector function 242 activity may be lower than for virion neutralization 32 ; if so, this property might clarify how 243 antibodies with reduced neutralizing potency against VOC that still bind spike protein on the 244 virion or surface of infected cells retain protective activity in vivo. with Dunnett's test; ns, not significant, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 329 0.0001). n, Summary of the EC 50 values for each mAb against the indicated SARS-CoV-2 strain. 6 (BA.2), or 7 (D614G and BA.1) dpi. Viral RNA levels in the lungs (g, j-k), nasal turbinates 370 (h), and nasal washes (i) were determined by RT-qPCR, and infectious virus in the lungs (j-k) 371 was measured by plaque assay (g-k; lines indicate median ± SEM.; g-i and j-k; n = 8 and 372 10 mice per group, respectively; two experiments; g-i; (Mann-Whitney test between isotype and 373 mAb treatment; ns, not significant; ** P < 0.01, ***, P < 0.001); j-k; one-way ANOVA with 374 Tukey's multiple comparisons test; ns, not significant; * P < 0.05, ** P < 0.01, ***, P < 0.001, 375 ****, P < 0.0001). ExpiCHO-S cells were seeded at 6 x 10 6 cells/mL in a volume of 5 mL in a 50 mL bioreactor. 509

The following day, cells were transfected with SARS-CoV-2 spike glycoprotein-encoding 

An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes 556 neutralization by therapeutic monoclonal antibodies

The SARS-CoV-2 monoclonal antibody combination, AZD7442, is 599 protective in non-human primates and has an extended half-life in humans

Structural 602 characterization of a human Fc fragment engineered for lack of effector functions

Mouse model 605 recapitulating human Fcγ receptor structural and functional diversity

Lack of Ronapreve (REGN-CoV; casirivimab and imdevimab) 608 virological efficacy against the SARS-CoV-2 Omicron variant (B.1.1.529) in K18-609 hACE2 mice. bioRxiv

LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 611 variants. bioRxiv

In vivo monoclonal antibody efficacy against SARS-CoV-2 variant 613 strains

A combination of two human neutralizing antibodies prevents SARS-615

CoV-2 infection in cynomolgus macaques

A Fc-enhanced NTD-binding non-neutralizing antibody 618 delays virus spread and synergizes with a nAb to protect mice from lethal SARS-CoV-2 619 infection

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and 621 its immune cross-reactivity with SARS-CoV

Antibody potency, effector function, and combinations in protection 624 and therapy for SARS-CoV-2 infection in vivo

Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing 627 antibodies require Fc function for optimal efficacy

Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 630 efficacy

Fc effector cross-reactivity: A hidden arsenal against 632 SARS-CoV-2's evasive maneuvering

SARS-CoV-2 Beta and Delta variants trigger Fc effector function 635 with increased cross-reactivity

A game of numbers: the stoichiometry of antibody-638 mediated neutralization of flavivirus infection

Characterization and antiviral susceptibility of SARS-CoV-2 641

SARS-CoV-2 Omicron-B. 1.1. 529 Variant leads to less severe 643 disease than Pango B and Delta variants strains in a mouse model of severe COVID-19

The omicron (B. 1.1. 529) SARS-CoV-2 variant of concern does not 646 readily infect Syrian hamsters

Lectins enhance SARS-CoV-2 infection and influence neutralizing 648 antibodies

Neutralizing and protective human monoclonal antibodies 650 recognizing the N-terminal domain of the SARS-CoV-2 spike protein

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the 653 ACE2 receptor

UCSF ChimeraX: Meeting modern challenges in visualization and 655 analysis

TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human 657 small intestinal enterocytes

Resistance of SARS-CoV-2 variants to neutralization by monoclonal 659 and serum-derived polyclonal antibodies

Identification of SARS-CoV-2 spike mutations that attenuate monoclonal 662 and serum antibody neutralization

A potently neutralizing SARS-CoV-2 antibody inhibits variants 665 of concern by utilizing unique binding residues in a highly conserved epitope

Growth, detection, 668 quantification, and inactivation of SARS-CoV-2

*** **